Get the Stockscreener App
1.75
1.69%
-0.03
Lava Therapeutics Nv stock is traded at $1.75, with a volume of 58,932.
It is down -1.69% in the last 24 hours and up +18.24% over the past month.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
See More
Previous Close:
$1.78
Open:
$1.76
24h Volume:
58,932
Relative Volume:
0.18
Market Cap:
$46.82M
Revenue:
$4.99M
Net Income/Loss:
$-28.29M
P/E Ratio:
-1.6622
EPS:
-1.0528
Net Cash Flow:
$-36.20M
1W Performance:
+9.37%
1M Performance:
+18.24%
6M Performance:
+38.89%
1Y Performance:
+12.54%
1-Day Range:
$1.745
$1.7716
1-Week Range:
$1.60
$1.825
52-Week Range:
$0.8502
$2.00
Lava Therapeutics Nv Stock (LVTX) Company Profile
Name
Lava Therapeutics Nv
Sector
Industry
Phone
31 6 3000 3035
Address
YALELAAN 62, UTRECHT
Compare LVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.75 | 46.82M | 4.99M | -28.29M | -36.20M | -1.0528 |
|
ARGX
Argen X Se Adr
|
920.00 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
201.58 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.65 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
354.65 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.92 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
View All
Lava Therapeutics Nv Stock (LVTX) Latest News
Will LAVA Therapeutics N.V. stock benefit from AI adoptionLong Setup & Real-Time Chart Breakout Alerts - newser.com
How LAVA Therapeutics N.V. stock performs during Fed tightening cyclesJuly 2025 Spike Watch & Low Risk High Win Rate Picks - newser.com
Why LAVA Therapeutics N.V. (4PKB) stock stays on buy listsWeekly Trade Analysis & Safe Swing Trade Setups - newser.com
Will LAVA Therapeutics N.V. (4PKB) stock justify high valuationJuly 2025 EndofMonth & Fast Exit and Entry Strategy Plans - newser.com
Will LAVA Therapeutics N.V. stock benefit from green energy trendsDip Buying & Stepwise Trade Execution Plans - newser.com
Will LAVA Therapeutics N.V. (4PKB) stock outperform small cap peersMarket Activity Recap & Free Daily Entry Point Trade Alerts - newser.com
How LAVA Therapeutics N.V. (4PKB) stock expands through international marketsJuly 2025 Big Picture & AI Optimized Trade Strategies - newser.com
What makes LAVA Therapeutics N.V. (4PKB) stock appealing to growth investors - newser.com
Published on: 2025-11-19 00:31:28 - newser.com
How LAVA Therapeutics N.V. (4PKB) stock trades in high volatilityWeekly Profit Summary & Weekly Top Performers Watchlists - newser.com
Analyzing LAVA Therapeutics N.V. with risk reward ratio chartsPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
Custom strategy builders for tracking LAVA Therapeutics N.V.July 2025 Levels & Weekly High Conviction Ideas - newser.com
Can LAVA Therapeutics N.V. (4PKB) stock expand revenue streamsJuly 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
LuxembourgXOMA Royalty Acquires LAVA Therapeutics - Mondaq
How LAVA Therapeutics N.V. stock valuations compare to rivals2025 Breakouts & Breakdowns & Low Risk Investment Opportunities - newser.com
How analysts revise price targets for LAVA Therapeutics N.V. (4PKB) stockJuly 2025 Trade Ideas & AI Powered Market Entry Ideas - newser.com
What drives LAVA Therapeutics NV 4PKB stock priceSwing Trading Watchlist & Double Digit Profit Strategies - earlytimes.in
Is LAVA Therapeutics N.V. showing signs of accumulationShort Setup & Low Drawdown Momentum Ideas - newser.com
Why hedge funds are buying LAVA Therapeutics N.V. stockMarket Trend Summary & Daily Momentum Trading Reports - newser.com
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lava Therapeutics Nv Stock (LVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 16 '25 |
Sale |
1.49 |
690,239 |
1,028,456 |
4,128,912 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 14 '25 |
Sale |
1.51 |
227,341 |
343,285 |
5,019,151 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 13 '25 |
Sale |
1.54 |
47,686 |
73,436 |
5,246,492 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 10 '25 |
Sale |
1.55 |
49,869 |
77,297 |
5,294,178 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 09 '25 |
Sale |
1.56 |
48,169 |
75,144 |
5,344,047 |
| Cooperatieve Gilde Healthcare | 10% Owner |
Oct 08 '25 |
Sale |
1.57 |
28,954 |
45,458 |
5,392,216 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
2,370,533 |
3,322,065 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 19 '25 |
Sale |
1.40 |
532,870 |
746,764 |
0 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 17 '25 |
Sale |
1.49 |
362,806 |
540,291 |
2,736,644 |
| Versant Venture Capital VI, L. | 10% Owner |
Sep 18 '25 |
Sale |
1.44 |
366,111 |
527,859 |
2,370,533 |
0.31%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):